Skip to main content
Premium Trial:

Request an Annual Quote

Eksigent Moves to Expanded Facilities in Dublin, Calif.

NEW YORK, Sept. 23 (GenomeWeb News) - Eksigent Technologies announced today that it has relocated its corporate headquarters to the CreeksideBusinessParkin Dublin, Calif.


With 43,000 square feet in space, the new facility is about double the size of the microfluidics provider's old headquarters in Livermore, Calif.It includes a customer demonstration center and research labs for the company's HPLC, medical device, and advanced technology product development.


Eksigent employs 70 people.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.